Women Face Treatment Gaps Despite Equal Heart Risk in Major Cardiovascular Study
Large analysis reveals women with heart-kidney-metabolic syndrome receive fewer proven therapies than men despite similar cardiovascular risks.
Summary
A major analysis of nearly 19,000 people with cardiovascular-kidney-metabolic syndrome found that women face significant treatment disparities despite having similar heart disease risks as men. Women were less likely to receive proven medications like statins, blood pressure drugs, and diabetes medications, even though they had higher rates of multiple health conditions. However, when women did receive the medication finerenone, it worked equally well in both sexes for preventing heart failure and kidney problems. This highlights a critical gap in healthcare where women aren't getting the same level of preventive treatment as men for serious metabolic conditions.
Detailed Summary
Cardiovascular-kidney-metabolic syndrome affects millions worldwide, combining heart disease, kidney problems, and diabetes into a dangerous cluster that significantly reduces lifespan. Understanding sex differences in this syndrome is crucial for optimizing treatment and extending healthy longevity.
Researchers analyzed data from 18,991 participants across three major clinical trials, following them for nearly three years. The study included people with chronic kidney disease, type 2 diabetes, and heart failure, representing real-world patients with advanced metabolic dysfunction.
The results revealed striking treatment disparities: women were significantly less likely to receive evidence-based medications including aspirin, statins, blood pressure medications, SGLT2 inhibitors, and GLP-1 receptor agonists. Despite this treatment gap, women and men had similar rates of heart failure hospitalization and cardiovascular death, though women had lower overall mortality risk.
Crucially, when women received the mineralocorticoid receptor antagonist finerenone, they experienced identical cardiovascular and kidney benefits as men. This suggests that biological sex doesn't affect drug efficacy, but healthcare delivery does.
For longevity optimization, this research highlights the importance of aggressive, evidence-based treatment regardless of sex. The medications showing disparities—particularly statins, SGLT2 inhibitors, and GLP-1 agonists—have proven longevity benefits beyond their primary indications. Women may need to advocate more assertively for these treatments.
The study's limitation is its focus on people with already-advanced disease, so prevention strategies weren't evaluated. However, the consistent drug efficacy across sexes suggests that personalized medicine protocols should emphasize equal access to proven therapies rather than sex-specific treatments for cardiovascular-metabolic health.
Key Findings
- Women received fewer proven heart and diabetes medications despite having similar cardiovascular risks as men
- Treatment with finerenone worked equally well in both sexes for preventing heart and kidney complications
- Women had 17% lower risk of death from any cause compared to men over three years
- Women were more likely to have multiple health conditions but less likely to get comprehensive treatment
Methodology
Pooled analysis of three randomized controlled trials including 18,991 participants with cardiovascular-kidney-metabolic syndrome. Median follow-up was 2.9 years with adjusted statistical models comparing outcomes between sexes.
Study Limitations
Study focused on people with advanced disease rather than prevention. Results may not apply to earlier stages of metabolic dysfunction or healthier populations seeking longevity optimization.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.